CD8A and neoplasm: In the same trial, the baseline presence of CD8+ and CD4+ TILs were also significantly greater in patients with disease control compared to those with progressive disease, with further increased tumour infiltration of CD4+ and CD8+ T cells following OV administration, only seen in patients with disease control [56].